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Background: This study was undertaken to identify the determinants of respiratory
symptom development in patients with chronic airflow obstruction (CAO).
Methods: Categories of symptomatic and asymptomatic CAO were defined using
questionnaire responses and spirometric results. We analyzed data obtained as part
of the second South Korean National Health and Nutrition Examination Survey
(Korean NHANES II).
Results: Among 187 patients with CAO, 69 had no respiratory symptoms. CAO
patients with symptoms were significantly older than those without symptoms
ðP ¼ 0:026Þ, and hypertension was more common among symptomatic CAO patients
than among asymptomatic CAO patients ðP ¼ 0:005Þ. According to questionnaire
responses, symptomatic CAO patients had more difficulty in walking or lifting
ðPo0:001Þ, required more help with personal care ðP ¼ 0:01Þ, and had poorerElsevier Ltd. All rights reserved.
650 5686; fax: +82 2 2655 2076.
r (J.H. Chang).
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Symptom determinants in chronic airflow obstruction 2171general health than asymptomatic CAO patients ðP ¼ 0:008Þ. Symptomatic CAO
patients had higher fasting blood glucose levels than asymptomatic CAO patients
ðP ¼ 0:028Þ. Symptomatic CAO patients had significantly lower forced expiratory
volume in 1 s (FEV1) ðP ¼ 0:001Þ, forced vital capacity (FVC) ðP ¼ 0:008Þ, and a ratio
of FEV1/FVC than asymptomatic CAO patients ðPo0:001Þ. Statistically significant
predictors of symptom development were as follows: age (odds ratio (OR) 1.04,
P ¼ 0:028), hypertension (OR 4.41, P ¼ 0:008), fasting blood glucose (OR 1.02,
P ¼ 0:034), FEV1 (OR 0.07, P ¼ 0:002), FVC (OR 0.08, P ¼ 0:009), FEV1/FVC (OR 0.00,
P ¼ 0:001). Multiple logistic regression analyses revealed two independent factors
associated with symptom development: FEV1/FVC (OR 0.001, P ¼ 0:002) and
hypertension (OR 5.95, P ¼ 0:005).
Conclusions: In CAO, respiratory symptom development is significantly associated
with low FEV1/FVC and the presence of hypertension.
& 2006 Elsevier Ltd. All rights reserved.N= 9,243 (>18 years)
Subjects included: n=187n=84
≥45 years
Spirometry
≥2 acceptable curves
FEV1/FVC < 0.7
Abnormal chest x-ray
n=3,755
n=2,101
n=1,673
n=271
Figure 1 Subject selection process.Introduction
Chronic obstructive pulmonary disease (COPD) is
currently the eighth leading cause of death in
Korea.1 It is the fourth in the United States and is
expected to become the third leading cause of
death by 2020.2 Cigarette smoking is the major risk
factor. However, despite its importance as a public
health problem, COPD is vastly underappreciated.
COPD is underdiagnosed and, when diagnosed,
commonly undertreated.3
Chronic airflow obstruction (CAO) is the main
feature of COPD,4 and undiagnosed airflow obstruc-
tion is common in population-based surveys.5–8
Moreover, the current symptom- or clinically-based
definitions of COPD are responsible for under-
estimations of the prevalence of this disease.
Spirometry is being advocated in general practice
for the early detection of CAO.9–11 However, in
clinical practice, only patients who present with
respiratory symptoms such as a cough, sputum,
and/or dyspnea are potential candidates for spiro-
metric testing. The presence of these symptoms
encourages patients and physicians to pay attention
to airway diseases. Although the early detection of
CAO is emphasized, it may be difficult to suspect or
diagnose asymptomatic cases of CAO.12
Generally, a forced expiratory volume in 1 s
(FEV1) less than 50% of predicted is likely to be
associated with impaired general health as well as
dyspnea.3 However, factors other than FEV1,
related to symptom occurrence in CAO patients,
have been less well investigated. To identify these
symptom determinants, we compared the demo-
graphic, socioeconomic, and spirometric data of
symptomatic and asymptomatic CAO patients and
constructed a logistic regression model. These data
used in this study were obtained from the second
South Korean National Health and Nutrition Exam-
ination Survey (Korean NHANES II).13Methods
Subjects
In Korean NHANES II, a stratified multistage
clustered probability design was used to select a
representative sample of civilian, non-institutiona-
lized Korean adults aged 18 years and older. We
divided Korea into 246,079 areas and, among these,
a final 200 survey areas were randomly selected by
geographic area, place of residence (urban/rural),
and residential pattern (apartment/non-apart-
ment). Finally, this nationwide survey was con-
ducted from selected 12,183 households in 2001. Of
3755 adults of 45 years of age or older, 2101
performed spirometry, and 1673 had more than two
acceptable curves. We excluded persons with other
respiratory diseases, such as tuberculosis or
bronchiectasis by chest radiography, which may
affect lung function (Fig. 1).
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The Korean NHANES II consisted of a household
questionnaire and a health examination administered
by trained examiners. Four categories of question-
naire items were used for this analysis; doctor’s
diagnosis of COPD or asthma; respiratory symptoms
(Table 1); cigarette smoking; and health impact.
Spirometry was performed with equipment that
met the American Thoracic Society (ATS) perfor-
mance criteria.14 Procedures for testing were based
on 1994 ATS recommendations.14Definitions
For this analysis, spirometry results were classified
using the Global Initiative for chronic obstructive
lung disease (GOLD) criteria.15 Airflow obstruction
was defined by a ratio of an FEV1 to a forced vital
capacity (FVC) (FEV1/FVC) below 0.7. The severity
of ventilatory impairment was classified using GOLD
criteria as follows: mild, FEV1X80% of predicted;
moderate, 50%pFEV1o80%; severe, 30%pFEV1o
50%; very severe, FEV1o30%. CAO was defined as
airflow obstruction in persons aged 45 years or
older in the absence of respiratory diseases affect-
ing airflow on chest radiographs.
Using eight questionnaire responses (Table 1),
symptomatic patients were defined as persons who
presented any one of the following symptoms of
cough, sputum, dyspnea, and wheezing, or had a
doctor’s diagnosis of COPD or asthma. In other
words, if any answer was ‘yes’, the case belonged
to symptomatic group.Statistical analysis
Statistical analysis was performed using SPSS-PC
for Windows Version 11.0. Descriptive data areTable 1 Questionnaires for respiratory symptoms and ph
Items
1. Has a doctor ever told you that you had chronic bronch
2. Do you bring up phlegm on most days for 3 consecutive
3. Do you usually cough on most days for 3 consecutive m
4. Are you troubled by shortness of breath when hurrying
5. Has a doctor ever told you that you had asthma?
6. Have you had wheezing or whistling in your chest at an
7. Have you had an attack of asthma (sudden bouts of coug
months?
8. Are you currently taking any medication, (including inh
bronchitis, emphysema or COPD?
COPD, chronic obstructive pulmonary disease.expressed as mean (SD) and frequencies are
expressed as number (%). Differences between
the two groups were tested using the Student t-
test or the w2-test. Determinants of respiratory
symptom development in patients with CAO were
identified using multiple logistic regression ana-
lyses. P-values of o0.05 were used to define
statistical significance.Results
Of 271 subjects with an FEV1/FVC of less than 0.7
by spirometry, 84 were excluded because of the
presence of lung lesions by chest radiography.
Finally, 187 were included using our definition of
CAO (Fig. 1), and of these 69 were asymptomatic.
Symptomatic CAO patients were significantly
older than asymptomatic patients ðP ¼ 0:026Þ, and
hypertension was more common among sympto-
matic than among asymptomatic patients ðP ¼
0:005Þ (Table 2).
In terms of life-style factors, e.g., smoking habit
and economic status, no difference was observed
between the two patient groups (Table 3).
Symptomatic CAO patients had more difficulty in
walking or lifting ðPo0:001Þ, needed more help
with personal care ðP ¼ 0:01Þ, and had poorer
general health than asymptomatic patients ðP ¼
0:008Þ (Table 4).
Laboratory tests showed that symptomatic
CAO patients had higher fasting blood glucose
levels than asymptomatic patients ðP ¼ 0:028Þ
(Table 5).
Spirometry tests showed that symptomatic CAO
patients had significantly lower FEV1 ðP ¼ 0:001Þ,
FVC ðP ¼ 0:008Þ, FEV1/FVC than asymptomatic CAO
patients ðPo0:001Þ. No asymptomatic patient had
severe airflow obstruction, defined as an FEV1 of
o50% of predicted (Table 6).ysician-diagnosed respiratory diseases.
itis, emphysema, or COPD?
months or more during the year?
onths or more during the year?
on level ground or walking uphill?
y time during the last 12 months?
h and shortness of breath with wheezing) in the last 12
alers, aerosols or tablets) for asthma, chronic
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Table 2 Demographic characteristics in CAO patients with or without symptom.
Variable No symptom (n ¼ 69) Symptom (n ¼ 118) P-value
Age (years) 61.079.7 64.078.5 0.026
Male sex, n (%) 52 (75.4) 94 (79.7) NS
Height (cm) 16378 16378 NS
Weight (kg) 61.6710.7 61.679.1 NS
Body mass index (kg/m2) 23.072.9 23.172.8 NS
Waist to hip ratio 0.9070.07 0.9270.06 NS
Systolic blood pressure (mmHg) 130718 131721 NS
Diastolic blood pressure (mmHg) 82711 79711 NS
Associated diseasey
Hypertension, n (%) 4 (5.8) 25 (21.4) 0.005
Diabetes mellitus, n (%) 1 (1.4) 9 (7.7) NS
Arthritis, n (%) 11 (15.9) 25 (21.2) NS
Values are expressed as mean7SD unless otherwise specified.
CAO, chronic airflow obstruction; NS, not significant.
AgeX45, FEV1/FVCo0.7, and no other lesion causing airflow obstruction in chest radiograph.
ySubjects who have already taken some medication for an associated disease.
Table 3 Lifestyle and economic status in CAO patients with or without symptom.
Variable No symptom (n ¼ 69) Symptom (n ¼ 118) P-value
Smoking NS
Smoker, n (%) 50 (72.5) 83 (70.3)
Current smoker, n (%) 34 (49.3) 56 (47.4)
Ex-smoker, n (%) 16 (23.2) 27 (22.9)
Never, n (%) 19 (27.5) 35 (29.7)
Age to start smoking (years) 22.476.3 22.075.0 NS
Smoking duration (years) 35.5711.8 38.4711.5 NS
Pack-years 23.2723.7 24.97 22.2 NS
Smoking cessation attempt, n (%) 11 (15.9) 27 (22.9) NS
Passive smoking, n (%) 27 (39.1) 50 (42.4) NS
Regular exercise, n (%) 22 (31.9) 29 (24.6) NS
Walking time (min/day) 1127207 71786 NS
Working time (days/week)y 5.971.3 5.971.4 NS
Working time (h/day)y 8.672.8 8.872.8 NS
Sleep (h/day) 6.871.7 6.871.5 NS
Health examination, n (%) 36 (52.2) 59 (50.0) NS
Living expenses (US$/month) 7607568 7057507 NS
Income (US$/month) 9757890 8917722 NS
Values are expressed as mean7SD unless otherwise specified.
NS, not significant.
Excluding those subjects who never smoked.
yIncluding those subjects with job (no symptom, n ¼ 6; symptom, n ¼ 33).
Symptom determinants in chronic airflow obstruction 2173The statistically significant predictors of symptom
development by bivariate analyses were as follows:
age (odds ratio (OR) 1.04, P ¼ 0:028), hypertension
(OR 4.41, P ¼ 0:008), fasting blood glucose (OR
1.02, P ¼ 0:034), FEV1 (OR 0.07, P ¼ 0:002), FVC
(OR 0.08, P ¼ 0:009), and FEV1/FVC (OR 0.00,P ¼ 0:001) (Table 7). However, multiple logistic
regression analyses revealed that two independent
factors were associated with symptom develop-
ment, i.e., FEV1/FVC (OR 0.001; 95% confidence
interval (CI) 0.00–0.07, P ¼ 0:002) and hypertension
(OR 5.95; 95% CI 1.69–20.95, P ¼ 0:005).
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Table 4 Health impact in CAO patients with or without symptom.
Variable No symptom (n ¼ 69) Symptom (n ¼ 118) P-value
Weight loss 13 (18.8) 32 (27.1) NS
Difficulty in walking or lifting o0.001
No 40 (58.8) 36 (30.5)
Some 24 (35.3) 51 (43.2)
Much 2 (2.9) 29 (24.6)
Unable 2 (2.9) 2 (1.7)
Help handling personal care 0.01
No need 67 (100) 106 (90.6)
Need 0 (0) 11 (9.4)
General health 0.008
Excellent 4 (5.8) 5 (4.2)
Very good 30 (43.5) 26 (22.0)
Good 18 (26.1) 36 (29.7)
Fair 16 (23.2) 39 (33.1)
Poor 1 (1.4) 13 (11.0)
Values are expressed as number (%).
Table 5 Biochemical characteristics in CAO patients with or without symptom.
Variable No symptom (n ¼ 69) Symptom (n ¼ 118) P-value
Hemoglobin (g/dL) 13.971.3 14.978.0 NS
Hematocrit (%) 42.374.1 43.376.7 NS
AST (IU/L) 25.8710.1 24.879.2 NS
ALT (IU/L) 20.479.6 21.4712.2 NS
Total cholesterol (mg/dL) 203734 194731 NS
Triglyceride (mg/dL) 159785 154779 NS
HDL cholesterol (mg/dL) 47.6713.1 44.1711.1 NS
Fasting blood glucose (mg/dL) 94715 100720 0.028
Hemoglobin A1c (%) 5.770.5 7.6712.1 NS
Blood urea nitrogen (mg/dL) 13.873.8 14.674.0 NS
Creatinine (mg/dL) 1.171.1 1.170.8 NS
Values are expressed as mean7SD.
AST, aspartate aminotransferase; ALT, alanine aminotransferase; HDL, high-density lipoprotein; NS, not significant.
Table 6 Lung function parameters and severity of airflow obstruction in CAO patients with or without symptom.
Variable No symptom (n ¼ 69) Symptom (n ¼ 118) P-value
FEV1 (% predicted) 84.9715.2 75.3721.6 0.001
FVC (% predicted) 99.2714.0 92.3718.3 0.008
FEV1/FVC (%) 64.675.8 59.6710.1 o0.001
COPD severity 0.004
Mild, n (%) 44 (63.8) 55 (46.6)
Moderate, n (%) 25 (36.2) 44 (37.3)
Severe, n (%) 0 (0) 16 (13.6)
Very severe, n (%) 0 (0) 3 (2.5)
Values are expressed as mean7SD unless otherwise specified.
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
GOLD15 criteria as follows: mild, FEV1X80% of predicted; moderate, 50%pFEV1o80%; severe, 30%p FEV1o 50%; very
severe, o30%
J.H. Chang et al.2174
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Table 7 The association between variables and the occurrence of symptoms in patients with airflow
obstruction.
Variable Odds ratio (95% confidence interval) P-value
Age (years) 1.04 (1.004–1.07) 0.028
Hypertension 4.41 (1.47–13.28) 0.008
Fasting blood glucose (mg/dL) 1.02 (1.002–1.04) 0.034
FEV1% predicted 0.07 (0.01–0.39) 0.002
FVC % predicted 0.08 (0.01–0.54) 0.009
FEV1/FVC (%) 0.00 (0.00–0.04) 0.001
FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity.
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Sixty-nine patients who had neither symptom nor
doctor’s diagnosis of COPD or asthma had signifi-
cant airflow limitation by spirometry testing even
though all of them showed mild to moderate airflow
obstruction according to the GOLD criteria.15
Bivariate analyses showed that age, hyperten-
sion, fasting blood glucose, FEV1, FVC, and FEV1/
FVC were significantly associated with symptom
occurrence in CAO. Although old age, hypertension,
and high fasting blood glucose levels are not
directly related to respiratory symptoms and/or
airway obstruction, all might encourage an indivi-
dual to seek a doctor’s advice,16,17 and if spirome-
try is performed, airflow obstruction would
probably be diagnosed.
It can be presumed that the degree of ventilatory
impairment affects subjective symptoms. In the
present study, no severe airflow obstruction (de-
fined as an FEV1 of o50% of predicted) was
observed in asymptomatic subjects. Bivariate ana-
lyses showed that each of the three spirometric
parameters was negatively associated with symp-
tom occurrence in CAO patients. However, multiple
logistic regression analyses revealed that FEV1/FVC
was the most significant factor of these factors.
FEV1/FVC is known to be able to reflect obstructive
ventilatory impairment better than FEV1.
18 Because
FEV1/FVC is a ratio, mild to moderate obstructive
disease can be identified without having to refer to
predicted values. Although severe CAO patients
have usually a low FVC and a low FEV1, FVC is not
considered as a marker of airflow obstruction.
In the present study, hypertension was the
second independent factor associated with symp-
tom occurrence in CAO. Tobacco smoking is an
etiologic factor of both COPD and systemic hyper-
tension, and is known to increase the impact of
hypertension as a risk factor for cardiovascular
disease.19 Epidemiologic studies have shown airflow
limitation to be an independent predictor of futurecardiovascular events in patients with various
cardiovascular risk factors.20,21 Moreover, isolated
systolic hypertension and emphysema may fre-
quently co-occur in the elderly, as both conditions
are strongly related to an advancing age.22
Of 168 subjects with mild to moderate airflow
obstruction defined as FEV1X50% of predicted, 41%
were completely asymptomatic. Vestbo and
Lange23 followed patients with GOLD stage 0 and
found that 11.6% and 18.5% of patients without
respiratory symptoms developed GOLD stage 1 or
worse after 1 and 15 years, respectively. Moreover,
Renwick and Connolly24 demonstrated that respira-
tory symptoms do not predict airflow obstruction,
and concluded that respiratory symptoms do not
identify adults with airflow obstruction. These
findings are consistent with our data that 37% of
CAO patients were asymptomatic and had never
been spirometry tested. These results suggest that
spirometric testing is mandatory for detection of
early stage of CAO. Previous studies conducted in
general practice have demonstrated that spirome-
try significantly improves COPD early detection
rates in general practice.11,12
The occurrence of respiratory symptoms can
make a patient aware of CAO and probably predicts
more severe airway disease. However, the absence
of symptoms is no indicator of the absence of CAO.
Of note, almost 10% of our subjects with CAO were
not only asymptomatic but were also never-
smokers (Table 3). Even in a national sample of
adults in the United States, undiagnosed airflow
obstruction was more common than doctor-diag-
nosed COPD or asthma, and 12.2–35.2% of women
with airflow obstruction had never smoked.3 More-
over, among 1315 subjects without airflow ob-
struction who responded eight respiratory ques-
tionnaires, 771 (58.6%) were symptomatic. This
means that symptom does not predict airflow
obstruction. Although a consensus statement from
the National Lung Health Education Program re-
commended that primary-care providers should
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years in order to detect COPD,10 spirometry testing
should be applied to diagnose COPD at the earliest
possible opportunity in all subjects ofX45 years of
age, irrespective of cigarette smoking.
In conclusion, FEV1/FVC was identified as the
most important determinant of symptom occur-
rence in CAO, and hypertension as the second most
important. Perhaps this means that hypertensive
subjects are more likely to be diagnosed as having
CAO than normotensive subjects. More than a third
of our subjects with CAO were asymptomatic and
without a doctor’s diagnosis of COPD or asthma,
even though they had an FEV1 of X50% of
predicted. We conclude that currently, spirometry
is the only diagnostic tool capable of detecting
early CAO in asymptomatic subjects.References
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